Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase Technology-High Kill Rate of Coronavirus (BSL-2)

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Feb 18, 2021 11:34pm

197 Views

Post# 32606645

RE:Theralase Technology-High Kill Rate of Coronavirus (BSL-2)

Something new. Not trialed yet for sensitivity and specificity through Health Canada -- so it could still take a lifetime.

"ISBRG's SpotLight-19© technology platform has proof of concept, and the funding now enables trials to determine the sensitivity and specificity of the device which will be compared to the accuracy of PCR tests in upcoming trials which are subject to authorization by Health Canada and REB review. Several published studies support ISBRG's proof of concept and the application of light to detect viruses has been well documented in the past, see (https://pubmed.ncbi.nlm.nih.gov/29806030/)."

Looks like an extension of their Zika Virus test kit:

Abstract

The accelerating global spread of arboviruses, such as Zika virus (ZIKV), highlights the need for more proactive mosquito surveillance. However, a major challenge during arbovirus outbreaks has been the lack of rapid and affordable tests for pathogen detection in mosquitoes. We show for the first time that near-infrared spectroscopy (NIRS) is a rapid, reagent-free, and cost-effective tool that can be used to noninvasively detect ZIKV in heads and thoraces of intact Aedes aegypti mosquitoes with prediction accuracies of 94.2 to 99.3% relative to quantitative reverse transcription polymerase chain reaction (RT-qPCR). NIRS involves simply shining a beam of light on a mosquito to collect a diagnostic spectrum. We estimated in this study that NIRS is 18 times faster and 110 times cheaper than RT-qPCR. We anticipate that NIRS will be expanded upon for identifying potential arbovirus hotspots to guide the spatial prioritization of vector control.

https://universalproptech.com/

SpotLight-19© technology platform features:

a non-invasive scan of a person's finger with a harmless beam of light
designed to provide confirmation of Covid-19 infection in less than 1 minute
low-cost testing.

ISBRG's SpotLight-19© technology is intended for use in large venues, such as: